Department of Medicinal Chemistry

Chengguo (Chris) Xing, Ph.D.

COP - Image - Size 3 - Xing_Chris
    Medicinal Chemistry
  • B.S., 1996
    Dalian University of Technology
  • Ph.D., 2001
    Arizona State University
  • Postdoctoral Associate, Department of Chemistry and Chemical Biology, 2003
    Harvard University
  • drug resistance
  • cancer therapy
  • prevention
  • organic synthesis
  • natural products
  • 2-125 Cancer & Cardiovascular Research Building
  • University of Minnesota
    College of Pharmacy
    Department of Medicinal Chemistry
    2231 Sixth Street SE #2-125
    Minneapolis, MN 55455

About Chengguo (Chris) Xing, Ph.D.

Xing’s independent research has been focusing on 1) identifying and developing natural and synthetic small-molecule based candidates for cancer prevention and treatment and elucidating their corresponding mechanisms of action, exemplified by the CXL and kava projects; 2) developing cutting- edge technologies for cancer early diagnosis and prognosis, represented by the GMR nanosensing project; and 3) investigating the potential and molecular basis of dietary supplements for disease prevention and treatment, illustrated by the Alzheimer’s disease and anxiety projects. The highly interdisciplinary nature of Xing’s research is built upon the research expertise in organic chemistry, biochemistry, molecular and cellular biology, and animal-based disease models, and extensive collaborations. These research projects are carried forward by a group of energetic scientists with high motivation, dedication, self-discipline, and a great heart to science that we are proud of.


Skibo, E. B. and Xing, C. Aziridinyl Quinone Antitumor Agents Based on Indoles and Cyclopent[b]indoles: Structure-Activity Relationships for Cytotoxicity and Antitumor Activity. U.S. Pat. Appl. Publ. 2003, US 2003139609.

Skibo, E. B. and Xing, C. Preparation of N-unsubstituted cytotoxic (aziridinyl)indolediones and (aziridinyl) cyclopent(b)indolediones for the treatment of cancer. U.S. Pat. Appl. Publ. 2004, US 20040006054.

Myers, A.; LaPorte, J.; Xing, C. Assay for identifying biological targets of polynucleotide-binding compounds. U.S. Appl. Publ. 2004, US 2004248100.

Xing, C.; Doshi, J. M. Therapeutic compounds, U. S. Patent, 2009, US2008057892.

Xing, C. and Wang, J. Nanosensor, U.S. Patent, 2009.

Published Works

Johnson, T. E.; Kassie, F.; O'Sullivan, M. G.; Negia, M.; Hanson, T. E.; Upadhyaya, P.; Ruvolo, P. P.; Hecht, S. S.; Xing, C.* Chemopreventive Effect of Kava on 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone Plus Benzo[a]pyrene-Induced Lung Tumorigenesis in A/J Mice. Cancer Prevention Research 2008, 1, 430-438. PMID: 19138990 [PubMed - indexed for MEDLINE].

Srinivasan, B.; Li, Y.; Jing, Y.; Xu, Y.; Xing, C.*; Wang, J. P.* A GMR sensor- and magnetic nanoparticle- based detecting system of zeptomol sensitivity: An integrated platform potentially leading to personalized medicine. Angew. Chem. Int. Ed. 2009, 48 (15):2764-2767. PMID: 19288507 [PubMed - indexed for MEDLINE].

Hermanson, D.; Addo, S. N.; Bajer, A.; Marchant, J.; Al-Mousa, F.; Michelangeli, F.; LeBien, T. W.; Xing, C.* Dual mechanisms of sHA 14-1 on mitochondria and endoplasmic reticulum in inducing apoptosis. Mol. Pharmacol. 2009 76 (3): 667-678. PMCID: PMC2730395.

Das, S. G.; Doshi, J. M.; Tian, D.; Addo, S. N.; Srinivasan, B.; Hermanson, D.; Xing, C.* Structure activity relationships and molecular mechanisms of sHA 14-1 and its analogs. J. Med. Chem. 2009, 52(19) 5937-5949. PMID: 19743858

Das, S. G.; Srinivasan, B.; Hermanson, D.; Bleeker, N.; Doshi, J. M.; Tang, R.; Beck, W. T.; Xing, C.* Structure Activity Relationship and Molecular Mechanisms of Ethyl 2-Amino 6-(3,5- Dimethoxyphenyl)-4-(2-Ethoxy-2-Oxoethyl)-4H-Chromene-3-Carboxylate (CXL017) and Its Analogue. J. Med. Chem. 2011, 54(16) 5937-5948. PMID: 21780800

Links & Downloads

  • ©2010 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on August 31, 2015